Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results ; volume:6 ; number:3 ; year:2021 ; pages:132-139 ; extent:8
Inflammatory intestinal diseases ; 6, Heft 3 (2021), 132-139 (gesamt 8)
- Urheber
-
Sagar, Rebecca
Lenti, Marco V.
Clark, Tanya
Rafferty, Helen J.
Gracie, David J.
Ford, Alexander C.
O’Connor, Anthony
Ahmad, Tariq
Hamlin, P. John
Selinger, Christian P.
- DOI
-
10.1159/000515593
- URN
-
urn:nbn:de:101:1-2021093000223555696178
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sagar, Rebecca
- Lenti, Marco V.
- Clark, Tanya
- Rafferty, Helen J.
- Gracie, David J.
- Ford, Alexander C.
- O’Connor, Anthony
- Ahmad, Tariq
- Hamlin, P. John
- Selinger, Christian P.
Ähnliche Objekte (12)
Bowel cancer chemoprevention - ready for the clinic?
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Biologics in therapy
Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Bowel cancer chemoprevention - ready for the clinic?
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Biologics in therapy
Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Bowel cancer chemoprevention - ready for the clinic?
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Biologics in therapy
Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
Moderne Antipsoriatika : Schwerpunkt Biologics